person · Reporting owner

Michels Douglas A

Disclosed activity across 3 companies

Tapewire entity: 49536
SEC CIK: 0001295391

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201	Director	May 04, 2026	May 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

WEST PHARMACEUTICAL SERVICES INC

Report date May 04, 2026 · Filed May 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	46,495.55	Reported balance After 2026-05-04 transaction · row 1 1 source row Row 1 · 2026-05-04 · Grant · Acquired 791 · Balance 46,495.55 F1: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

Filing footnotes · ownership attribution and instrument terms

F1: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ORASURE TECHNOLOGIES INC

Report date March 31, 2018 · Filed April 03, 2018

Section 16 reporting ended · disclosed 2018-04-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	Direct	660,861	Reported balance After 2018-03-31 transaction · row 1 1 source row Row 1 · 2018-03-31 · Tax withholding · Disposed 56,078 · Balance 660,861 F1: Withholding of shares to pay the tax liability associated with vesting of restricted shares.

Filing footnotes · ownership attribution and instrument terms

F1: Withholding of shares to pay the tax liability associated with vesting of restricted shares.

TYME TECHNOLOGIES, INC.

Report date September 16, 2022 · Filed September 16, 2022

Section 16 reporting ended · disclosed 2022-09-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-09-16 transaction · row 1 1 source row Row 1 · 2022-09-16 · Disposition to issuer · Disposed 110,000 · Balance 0 F1: Disposed of pursuant to the merger agreement between the issuer and Syros Pharmaceuticals, Inc. ("Syros") in exchange for 4,820 shares of Syros common stock having a market value of $7.30 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares.
Director Stock Option - Option to buySEC Table II · derivative / convertible security · Conversion / exercise price $2.71 · Expires 2028-10-01	Direct	Reported balance After 2022-09-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-09-16 · Disposition to issuer · Disposed 45,833 · Balance 0 F2: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,008 shares of Syros common stock for $61.84 per share, after giving effect to the Reverse Split.
Director Stock Option - Option to buySEC Table II · derivative / convertible security · Conversion / exercise price $2.71 · Expires 2028-10-01	Direct	Reported balance After 2022-09-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-09-16 · Disposition to issuer · Disposed 100,000 · Balance 0 F3: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 4,382 shares of Syros common stock for $61.84 per share, after giving effect to the Reverse Split.
Director Stock Option - Option to buySEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2029-08-22	Direct	Reported balance After 2022-09-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-09-16 · Disposition to issuer · Disposed 50,000 · Balance 0 F4: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $26.93 per share, after giving effect to the Reverse Split.
Director Stock Option - Option to buySEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2030-08-19	Direct	Reported balance After 2022-09-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-09-16 · Disposition to issuer · Disposed 65,000 · Balance 0 F5: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,848 shares of Syros common stock for $27.84 per share, after giving effect to the Reverse Split.
Director Stock Option - Option to buySEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2031-08-23	Direct	Reported balance After 2022-09-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-09-16 · Disposition to issuer · Disposed 88,000 · Balance 0 F6: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $25.10 per share, after giving effect to the Reverse Split.
Director Stock Option - Option to buySEC Table II · derivative / convertible security · Conversion / exercise price $0.31 · Expires 2032-08-23	Direct	Reported balance After 2022-09-16 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-09-16 · Disposition to issuer · Disposed 88,000 · Balance 0 F7: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the merger agreement between the issuer and Syros Pharmaceuticals, Inc. ("Syros") in exchange for 4,820 shares of Syros common stock having a market value of $7.30 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares.

F2: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,008 shares of Syros common stock for $61.84 per share, after giving effect to the Reverse Split.

F3: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 4,382 shares of Syros common stock for $61.84 per share, after giving effect to the Reverse Split.

F4: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $26.93 per share, after giving effect to the Reverse Split.

F5: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,848 shares of Syros common stock for $27.84 per share, after giving effect to the Reverse Split.

F6: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $25.10 per share, after giving effect to the Reverse Split.

F7: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 04, 2026 Filed May 6, 2026 21:35 UTC	WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201	GrantCommon Stock	791	$0.00	$0.00	Disclosure SEC source: 0000105770-26-000065 · form4.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,495.55 F1 · shares: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document
May 06, 2025 Filed May 8, 2025 21:04 UTC	WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201	GrantCommon Stock	1,071	$0.00	$0.00	Disclosure SEC source: 0001127602-25-013728 · form4.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,171.05 F1 · shares: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document
April 23, 2024 Filed Apr 25, 2024 20:50 UTC	WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201	GrantCommon Stock	564	$0.00	$0.00	Disclosure SEC source: 0001127602-24-013407 · form4.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,100.05 F1 · shares: These shares of restricted stock units will vest in full at the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document
April 25, 2023 Filed Apr 27, 2023 21:06 UTC	WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201	GrantCommon Stock	616	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-23-003693 · primarydocument.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,536.05 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of the grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document
September 16, 2022 Filed Sep 16, 2022 22:00 UTC	TYME TECHNOLOGIES, INC. TYME · Entity 123718	Disposition to issuerDirector Stock Option - Option to buy · Derivative	88,000	Not disclosed Strike: $0.31	Not disclosed	Disclosure SEC source: 0000899243-22-031352 · doc4.xml · derivative · entry 7 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 88,000 shares Expires 2032-08-23 F7 · price: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split. F7 · derivative.exercise_date: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split. Read SEC document
September 16, 2022 Filed Sep 16, 2022 22:00 UTC	TYME TECHNOLOGIES, INC. TYME · Entity 123718	Disposition to issuerDirector Stock Option - Option to buy · Derivative	88,000	Not disclosed Strike: $1.10	Not disclosed	Disclosure SEC source: 0000899243-22-031352 · doc4.xml · derivative · entry 6 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 88,000 shares Expires 2031-08-23 F6 · price: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $25.10 per share, after giving effect to the Reverse Split. F6 · derivative.exercise_date: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $25.10 per share, after giving effect to the Reverse Split. Read SEC document
September 16, 2022 Filed Sep 16, 2022 22:00 UTC	TYME TECHNOLOGIES, INC. TYME · Entity 123718	Disposition to issuerDirector Stock Option - Option to buy · Derivative	65,000	Not disclosed Strike: $1.22	Not disclosed	Disclosure SEC source: 0000899243-22-031352 · doc4.xml · derivative · entry 5 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,000 shares Expires 2030-08-19 F5 · price: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,848 shares of Syros common stock for $27.84 per share, after giving effect to the Reverse Split. F5 · derivative.exercise_date: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,848 shares of Syros common stock for $27.84 per share, after giving effect to the Reverse Split. Read SEC document
September 16, 2022 Filed Sep 16, 2022 22:00 UTC	TYME TECHNOLOGIES, INC. TYME · Entity 123718	Disposition to issuerDirector Stock Option - Option to buy · Derivative	50,000	Not disclosed Strike: $1.18	Not disclosed	Disclosure SEC source: 0000899243-22-031352 · doc4.xml · derivative · entry 4 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2029-08-22 F4 · price: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $26.93 per share, after giving effect to the Reverse Split. F4 · derivative.exercise_date: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $26.93 per share, after giving effect to the Reverse Split. Read SEC document
September 16, 2022 Filed Sep 16, 2022 22:00 UTC	TYME TECHNOLOGIES, INC. TYME · Entity 123718	Disposition to issuerDirector Stock Option - Option to buy · Derivative	100,000	Not disclosed Strike: $2.71	Not disclosed	Disclosure SEC source: 0000899243-22-031352 · doc4.xml · derivative · entry 3 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2028-10-01 F3 · price: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 4,382 shares of Syros common stock for $61.84 per share, after giving effect to the Reverse Split. F3 · derivative.exercise_date: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 4,382 shares of Syros common stock for $61.84 per share, after giving effect to the Reverse Split. Read SEC document
September 16, 2022 Filed Sep 16, 2022 22:00 UTC	TYME TECHNOLOGIES, INC. TYME · Entity 123718	Disposition to issuerDirector Stock Option - Option to buy · Derivative	45,833	Not disclosed Strike: $2.71	Not disclosed	Disclosure SEC source: 0000899243-22-031352 · doc4.xml · derivative · entry 2 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,833 shares Expires 2028-10-01 F2 · price: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,008 shares of Syros common stock for $61.84 per share, after giving effect to the Reverse Split. F2 · derivative.exercise_date: This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,008 shares of Syros common stock for $61.84 per share, after giving effect to the Reverse Split. Read SEC document
September 16, 2022 Filed Sep 16, 2022 22:00 UTC	TYME TECHNOLOGIES, INC. TYME · Entity 123718	Disposition to issuerCommon Stock	110,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-031352 · doc4.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to the merger agreement between the issuer and Syros Pharmaceuticals, Inc. ("Syros") in exchange for 4,820 shares of Syros common stock having a market value of $7.30 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares. Read SEC document
August 24, 2022 Filed Aug 29, 2022 10:30 UTC	TYME TECHNOLOGIES, INC. TYME · Entity 123718	GrantDirector Stock Option - Option to buy · Derivative	88,000	$0.00 Strike: $0.31	$0.00	Disclosure SEC source: 0000899243-22-029937 · doc4.xml · derivative · entry 1 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,000 Underlying: Common Stock · 88,000 shares Expires 2032-08-23 F1 · derivative.exercise_date: This option vests over a one-year period in equal quarterly installments. Read SEC document
May 24, 2022 Filed May 26, 2022 19:48 UTC	WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201	GrantCommon Stock	632	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-22-004427 · primarydocument.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,920.05 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document
August 24, 2021 Filed Aug 26, 2021 20:37 UTC	TYME TECHNOLOGIES, INC. TYME · Entity 123718	GrantDirector Stock Option - Option to buy · Derivative	88,000	$0.00 Strike: $1.10	$0.00	Disclosure SEC source: 0000899243-21-034271 · doc4.xml · derivative · entry 1 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,000 Underlying: Common Stock · 88,000 shares Expires 2031-08-23 F1 · derivative.exercise_date: This option vests over a one-year period in equal quarterly installments. Read SEC document
May 04, 2021 Filed May 6, 2021 23:28 UTC	WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201	GrantCommon Stock	577	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-21-003307 · primarydocument.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,288.05 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document
September 01, 2020 Filed Sep 3, 2020 20:18 UTC	TYME TECHNOLOGIES, INC. TYME · Entity 123718	PurchaseCommon Stock	50,000	$0.96	$48,000.00	Disclosure SEC source: 0000899243-20-024097 · doc4.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.95 to $0.96, inclusive. The reporting person undertakes to provide to Tyme Technologies, Inc., any security holder of Tyme Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document
August 20, 2020 Filed Aug 24, 2020 21:41 UTC	TYME TECHNOLOGIES, INC. TYME · Entity 123718	GrantDirector Stock Option - right to buy · Derivative	65,000	$0.00 Strike: $1.22	$0.00	Disclosure SEC source: 0000899243-20-023317 · doc4.xml · derivative · entry 1 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2020-08-20 F1 · derivative.exercise_date: This option, granted as annual compensation for director service, vests over a one-year period in four equal quarterly installments. Read SEC document
May 05, 2020 Filed May 7, 2020 22:08 UTC	WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201	GrantCommon Stock	975	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-20-003468 · primarydocument.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,616.1315 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document
August 22, 2019 Filed Aug 27, 2019 13:31 UTC	TYME TECHNOLOGIES, INC. TYME · Entity 123718	GrantDirector Stock Option - Right to Buy · Derivative	50,000	$0.00 Strike: $1.18	$0.00	Disclosure SEC source: 0000899243-19-022493 · doc4.xml · derivative · entry 1 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-08-21 F1 · derivative.exercise_date: This option, granted as annual compensation for director service, vests over a one-year period in four equal quarterly installments. Read SEC document
May 07, 2019 Filed May 9, 2019 19:10 UTC	WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201	GrantCommon Stock	1,565	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-19-002728 · primarydocument.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,276.9464 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document
February 14, 2019 Filed Feb 19, 2019 21:50 UTC	TYME TECHNOLOGIES, INC. TYME · Entity 123718	PurchaseCommon Stock	20,000	$3.26	$65,200.00	Disclosure SEC source: 0000899243-19-004078 · doc4.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.24 to $3.30, inclusive. The reporting person undertakes to provide to Tyme Technologies, Inc., any security holder of Tyme Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document
December 31, 2018 Filed Jan 3, 2019 21:13 UTC	WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201	GrantPhantom Stock Unit · Derivative	255	$98.03	$24,997.65	Disclosure SEC source: 0001562180-19-000127 · primarydocument.xml · derivative · entry 2 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,997.5421 Underlying: Common Stock · 255 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document
October 01, 2018 Filed Oct 3, 2018 22:52 UTC	TYME TECHNOLOGIES, INC. TYME · Entity 123718	GrantDirector Stock Option - right to buy · Derivative	45,833	$0.00 Strike: $2.71	$0.00	Disclosure SEC source: 0000899243-18-026105 · doc4.xml · derivative · entry 2 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,833 Underlying: Common Stock · 45,833 shares Expires 2028-10-01 F2 · derivative.exercise_date: This option, granted as pro-rated annual compensation for director service, vests over a one-year period in four equal quarterly installments. Read SEC document
October 01, 2018 Filed Oct 3, 2018 22:52 UTC	TYME TECHNOLOGIES, INC. TYME · Entity 123718	GrantDirector Stock Option - right to buy · Derivative	100,000	$0.00 Strike: $2.71	$0.00	Disclosure SEC source: 0000899243-18-026105 · doc4.xml · derivative · entry 1 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-10-01 F1 · derivative.exercise_date: This option, granted as a standard sign-on award for director service, vests over a one-year period in four equal quarterly installments. Read SEC document
September 28, 2018 Filed Oct 2, 2018 17:02 UTC	WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201	GrantPhantom Stock Unit · Derivative	203	$123.74	$25,119.22	Disclosure SEC source: 0001562180-18-004086 · primarydocument.xml · derivative · entry 2 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,742.5421 Underlying: Common Stock · 203 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. Read SEC document
June 29, 2018 Filed Aug 1, 2018 20:35 UTC	WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201	GrantPhantom Stock Unit · Derivative	271.808	$99.29	$26,987.82	Disclosure SEC source: 0001562180-18-003447 · primarydocument.xml · derivative · entry 4 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,539.5421 Underlying: Common Stock · 271.808 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. Read SEC document
May 01, 2018 Filed May 3, 2018 21:45 UTC	WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201	GrantCommon Stock	1,824	$0.00	$0.00	Disclosure SEC source: 0001562180-18-002195 · primarydocument.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,607.3235 F1 · price: These shares of restricted stock units will vest in full on the first anniversay of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document
March 31, 2018 Filed Apr 3, 2018 20:26 UTC	ORASURE TECHNOLOGIES INC OSUR · Entity 6152	Tax withholdingCommon stock	56,078	$16.80	$941,830.01	Disclosure SEC source: 0001209784-18-000014 · edgar.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 660,861 F1 · kind: Withholding of shares to pay the tax liability associated with vesting of restricted shares. Read SEC document
March 29, 2018 Filed Aug 1, 2018 20:35 UTC	WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201	GrantPhantom Stock Unit · Derivative	299.7101	$86.72	$25,990.86	Disclosure SEC source: 0001562180-18-003447 · primarydocument.xml · derivative · entry 3 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,267.7341 Underlying: Common Stock · 299.7101 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. Read SEC document
February 03, 2018 Filed Feb 5, 2018 23:02 UTC	ORASURE TECHNOLOGIES INC OSUR · Entity 6152	Tax withholdingCommon stock	8,736	$21.00	$183,456.00	Disclosure SEC source: 0001209784-18-000006 · edgar.xml · nonDerivative · entry 4 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 716,939 F1 · kind: Withholding of shares to pay the tax liability associated with vesting of restricted shares. Read SEC document
February 01, 2018 Filed Feb 5, 2018 23:02 UTC	ORASURE TECHNOLOGIES INC OSUR · Entity 6152	GrantCommon stock	36,615	Not disclosed	Not disclosed	Disclosure SEC source: 0001209784-18-000006 · edgar.xml · nonDerivative · entry 3 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 725,675 F2 · kind: Grant of restricted shares under the OraSure Technologies, Inc. Stock Award Plan, cliff vesting on March 31, 2018. F2 · price: Grant of restricted shares under the OraSure Technologies, Inc. Stock Award Plan, cliff vesting on March 31, 2018. Read SEC document
February 01, 2018 Filed Feb 5, 2018 23:02 UTC	ORASURE TECHNOLOGIES INC OSUR · Entity 6152	Tax withholdingCommon stock	27,985	$21.65	$605,735.33	Disclosure SEC source: 0001209784-18-000006 · edgar.xml · nonDerivative · entry 2 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 689,060 F1 · kind: Withholding of shares to pay the tax liability associated with vesting of restricted shares. Read SEC document
January 10, 2018 Filed Feb 5, 2018 23:02 UTC	ORASURE TECHNOLOGIES INC OSUR · Entity 6152	GiftCommon stock	3,090	$19.39	$59,915.10	Disclosure SEC source: 0001209784-18-000006 · edgar.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 717,045 Read SEC document
December 29, 2017 Filed Aug 1, 2018 20:35 UTC	WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201	GrantPhantom Stock Unit · Derivative	268.2856	$99.16	$26,603.20	Disclosure SEC source: 0001562180-18-003447 · primarydocument.xml · derivative · entry 2 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,968.024 Underlying: Common Stock · 268.2856 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. Read SEC document
October 04, 2017 Filed Oct 6, 2017 20:44 UTC	ORASURE TECHNOLOGIES INC OSUR · Entity 6152	SaleCommon stock	22,923	$23.00	$527,229.00	Disclosure SEC source: 0001209784-17-000059 · edgar.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 720,135 F1 · kind: Sale pursuant to a predetermined sales plan, entered into on August 29, 2017 under Rule 10b5-1 of the Securities and Exchange Act of 1934. Read SEC document
September 29, 2017 Filed Oct 3, 2017 19:54 UTC	WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201	GrantPhantom Stock Unit · Derivative	259.5246	$96.33	$25,000.00	Disclosure SEC source: 0001562180-17-003162 · primarydocument.xml · derivative · entry 2 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,699.7384 Underlying: Common Stock · 259.5246 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document
September 29, 2017 Filed Oct 3, 2017 21:07 UTC	ORASURE TECHNOLOGIES INC OSUR · Entity 6152	SaleCommon stock	25,000	$22.55	$563,712.50	Disclosure SEC source: 0001209784-17-000058 · edgar.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 743,058 F1 · kind: Sale pursuant to a predetermined sales plan, entered into on August 29, 2017 under Rule 10b5-1 of the Securities and Exchange Act of 1934. Read SEC document
June 30, 2017 Filed Jul 5, 2017 16:39 UTC	WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201	GrantPhantom Stock Unit · Derivative	264.8586	$94.39	$25,000.00	Disclosure SEC source: 0001562180-17-002373 · primarydocument.xml · derivative · entry 2 Michels Douglas A · CIK 0001295391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,423.1663 Underlying: Common Stock · 264.8586 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document
June 27, 2017 Filed Jun 29, 2017 23:49 UTC	ORASURE TECHNOLOGIES INC OSUR · Entity 6152	Exercise / conversionNonqualified stock options · Derivative	89,541	$0.00 Strike: $9.31	$0.00	Disclosure SEC source: 0001209784-17-000052 · edgar.xml · derivative · entry 9 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,378 Underlying: Common stock · 89,541 shares Expires 2025-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Nonqualified stock options granted on February 3, 2015 vesting and exercisable over a four-year period, with one-fourth of the options vesting on the first anniversary date of the grant and the remainder vesting ratably on a monthly basis, over the remaining 36 months. F3 · derivative.exercise_date: Nonqualified stock options granted on February 3, 2015 vesting and exercisable over a four-year period, with one-fourth of the options vesting on the first anniversary date of the grant and the remainder vesting ratably on a monthly basis, over the remaining 36 months. Read SEC document
June 27, 2017 Filed Jun 29, 2017 23:49 UTC	ORASURE TECHNOLOGIES INC OSUR · Entity 6152	Exercise / conversionNonqualified stock options · Derivative	75,000	$0.00 Strike: $11.30	$0.00	Disclosure SEC source: 0001209784-17-000052 · edgar.xml · derivative · entry 8 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 75,000 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Nonqualified stock options granted on February 1, 2012 vesting and exercisable over a four-year period, with one-fourth of the options vesting on the first anniversary date of the grant and the remainder vesting ratably on a monthly basis, over the remaining 36 months. F2 · derivative.exercise_date: Nonqualified stock options granted on February 1, 2012 vesting and exercisable over a four-year period, with one-fourth of the options vesting on the first anniversary date of the grant and the remainder vesting ratably on a monthly basis, over the remaining 36 months. Read SEC document
June 27, 2017 Filed Jun 29, 2017 23:49 UTC	ORASURE TECHNOLOGIES INC OSUR · Entity 6152	Exercise / conversionNonqualified stock options · Derivative	125,954	$0.00 Strike: $11.30	$0.00	Disclosure SEC source: 0001209784-17-000052 · edgar.xml · derivative · entry 7 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 125,954 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Nonqualified stock options granted on February 1, 2012 vesting and exercisable over a four-year period, with one-fourth of the options vesting on the first anniversary date of the grant and the remainder vesting ratably on a monthly basis, over the remaining 36 months. F2 · derivative.exercise_date: Nonqualified stock options granted on February 1, 2012 vesting and exercisable over a four-year period, with one-fourth of the options vesting on the first anniversary date of the grant and the remainder vesting ratably on a monthly basis, over the remaining 36 months. Read SEC document
June 27, 2017 Filed Jun 29, 2017 23:49 UTC	ORASURE TECHNOLOGIES INC OSUR · Entity 6152	SaleCommon stock	89,541	$16.28	$1,457,817.02	Disclosure SEC source: 0001209784-17-000052 · edgar.xml · nonDerivative · entry 6 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 768,058 F1 · kind: Sale pursuant to a predetermined sales plan, entered into on May 24, 2017, under Rule 10b5-1 of the Securities and Exchange Act of 1934. Read SEC document
June 27, 2017 Filed Jun 29, 2017 23:49 UTC	ORASURE TECHNOLOGIES INC OSUR · Entity 6152	SaleCommon stock	75,000	$16.67	$1,250,475.00	Disclosure SEC source: 0001209784-17-000052 · edgar.xml · nonDerivative · entry 5 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 857,599 F1 · kind: Sale pursuant to a predetermined sales plan, entered into on May 24, 2017, under Rule 10b5-1 of the Securities and Exchange Act of 1934. Read SEC document
June 27, 2017 Filed Jun 29, 2017 23:49 UTC	ORASURE TECHNOLOGIES INC OSUR · Entity 6152	SaleCommon stock	125,954	$17.13	$2,157,969.88	Disclosure SEC source: 0001209784-17-000052 · edgar.xml · nonDerivative · entry 4 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 932,599 F1 · kind: Sale pursuant to a predetermined sales plan, entered into on May 24, 2017, under Rule 10b5-1 of the Securities and Exchange Act of 1934. Read SEC document
June 27, 2017 Filed Jun 29, 2017 23:49 UTC	ORASURE TECHNOLOGIES INC OSUR · Entity 6152	Exercise / conversionCommon stock	89,541	$9.31	$833,179.01	Disclosure SEC source: 0001209784-17-000052 · edgar.xml · nonDerivative · entry 3 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,058,553 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 27, 2017 Filed Jun 29, 2017 23:49 UTC	ORASURE TECHNOLOGIES INC OSUR · Entity 6152	Exercise / conversionCommon stock	75,000	$11.30	$847,125.00	Disclosure SEC source: 0001209784-17-000052 · edgar.xml · nonDerivative · entry 2 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 969,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 27, 2017 Filed Jun 29, 2017 23:49 UTC	ORASURE TECHNOLOGIES INC OSUR · Entity 6152	Exercise / conversionCommon stock	125,954	$11.30	$1,422,650.43	Disclosure SEC source: 0001209784-17-000052 · edgar.xml · nonDerivative · entry 1 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 894,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 09, 2017 Filed May 11, 2017 21:29 UTC	ORASURE TECHNOLOGIES INC OSUR · Entity 6152	Exercise / conversionNonqualified stock options · Derivative	195,833	$0.00 Strike: $5.71	$0.00	Disclosure SEC source: 0001209784-17-000038 · edgar.xml · derivative · entry 5 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 195,833 shares Expires 2024-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Nonqualified stock options granted on February 3, 2014 vesting and exercisable over a four-year period, with one-fourth of the options vesting on the first anniversary date of the grant and the remainder vesting ratably on a monthly basis, over the remaining 36 months. Read SEC document
May 09, 2017 Filed May 11, 2017 21:29 UTC	ORASURE TECHNOLOGIES INC OSUR · Entity 6152	Exercise / conversionNonqualified stock options · Derivative	13,967	$0.00 Strike: $7.05	$0.00	Disclosure SEC source: 0001209784-17-000038 · edgar.xml · derivative · entry 4 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 13,967 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Nonqualified stock options granted on February 1, 2013 vesting and exercisable over a four-year period, with one-fourth of the options vesting on the first anniversary date of the grant and the remainder vesting ratably on a monthly basis, over the remaining 36 months. Read SEC document
May 09, 2017 Filed May 11, 2017 21:29 UTC	ORASURE TECHNOLOGIES INC OSUR · Entity 6152	SaleCommon stock	209,800	$15.01	$3,149,098.00	Disclosure SEC source: 0001209784-17-000038 · edgar.xml · nonDerivative · entry 3 Michels Douglas A · CIK 0001295391 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 768,058 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.